Advertisement
Advertisement

INBX

INBX logo

Inhibrx Biosciences, Inc. Common Stock

76.27
USD
Sponsored
+3.85
+5.31%
Jan 30, 16:00 UTC -5
Closed
exchange

Pre-Market

76.04

-0.23
-0.30%

INBX Earnings Reports

Positive Surprise Ratio

INBX beat 10 of 21 last estimates.

48%

Next Report

Date of Next Report
Mar 16, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$2.11
Implied change from Q3 25 (Revenue/ EPS)
--
/
-7.05%
Implied change from Q4 24 (Revenue/ EPS)
-100.00%
/
-31.72%

Inhibrx Biosciences, Inc. Common Stock earnings per share and revenue

On Nov 14, 2025, INBX reported earnings of -2.27 USD per share (EPS) for Q3 25, missing the estimate of -1.75 USD, resulting in a -30.11% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +6.04% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analysts forecast an EPS of -2.11 USD, with revenue projected to reach -- USD, implying an decrease of -7.05% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, Inhibrx Biosciences, Inc. Common Stock reported EPS of -$2.27, missing estimates by -30.11%, and revenue of $0.00, 0% as expectations.
The stock price moved up 6.04%, changed from $74.62 before the earnings release to $79.13 the day after.
The next earning report is scheduled for Mar 16, 2026.
Based on 3 analysts, Inhibrx Biosciences, Inc. Common Stock is expected to report EPS of -$2.11 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement